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Abstract
Background Implant-related infections represent one of
the most severe complications in orthopaedics. A fast-
resorbable, antibacterial-loaded hydrogel may reduce or
prevent bacterial colonization and biofilm formation of
implanted biomaterials.
Questions/purposes We asked: (1) Is a fast-resorbable
hydrogel able to deliver antibacterial compounds in vitro?
(2) Can a hydrogel (alone or antibacterial-loaded) coating
on implants reduce bacterial colonization? And (3) is
intraoperative coating feasible and resistant to press-fit
implant insertion?
Methods We tested the ability of Disposable Antibacterial
Coating (DAC) hydrogel (Novagenit Srl, Mezzolombardo,
Italy) to deliver antibacterial agents using spectropho-
tometry and a microbiologic assay. Antibacterial and
antibiofilm activity were determined by broth microdi-
lution and a crystal violet assay, respectively. Coating
resistance to press-fit insertion was tested in rabbit tibias
and human femurs.
Results Complete release of all tested antibacterial com-
pounds was observed in less than 96 hours. Bactericidal
and antibiofilm effect of DAC hydrogel in combination
with various antibacterials was shown in vitro. Approxi-
mately 80% of the hydrogel coating was retrieved on the
implant after press-fit insertion.
Conclusions Implant coating with an antibacterial-loaded
hydrogel reduces bacterial colonization and biofilm for-
mation in vitro.
Clinical Relevance A fast-resorbable, antibacterial-
loaded hydrogel coating may help prevent implant-related
infections in orthopaedics. However, further validation in
animal models and properly controlled human studies is
required.
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Introduction
Once a biofilm has been formed on an implant’s surface, it
is difficult to treat the infection because the bacteria
residing in the biofilm are protected from both phagocy-
tosis and antibiotics. Evidence shows the role of biofilms as
an impenetrable mechanical barrier against soluble agents
[5, 34, 42] and this explains why, over the last decades,
systemic antibiotics have shown their limits in treatment
and prevention of biofilm-related infections [28, 29, 42].
To prevent bacterial colonization of implanted bioma-
terials, various antibacterial surface coatings have been
proposed, but current technologies are far from large-scale
application in orthopaedics due to various limitations,
including questionable long-term effect on bacterial resis-
tance and on bone ingrowth, regulatory issues, and costs [1,
4, 17, 23, 37, 39]. In this evolving panorama, a fast-re-
sorbable antibacterial-loaded hydrogel coating may
theoretically offer (1) efficacy toward early bacterial col-
onization, providing complete protection of the implant for
the time needed to win the ‘‘race to the surface,’’ ie, in the
first hours after surgery; (2) safety, as high local concen-
tration and fast and complete release of the antibacterial
may avoid induction of antibiotic resistance and possible
risks of long-term effects on bone healing; (3) versatility,
through intraoperative mixing with a choice of different
antibacterial agents; (4) ease of handling; and (5) reduced
costs for large-scale application.
In this preclinical multiinstitutional study, we investi-
gated (1) the ability of a fast-resorbable hydrogel to deliver
different antibiotic and antibiofilm compounds locally; (2)
the ability of the hydrogel coating, alone and in combina-
tion with antibacterial agents, to reduce or prevent bacterial
colonization and biofilm formation on biomaterials com-
monly used in orthopaedics in vitro; and (3) the feasibility
of intraoperative coating of a standard joint prosthesis and
the capability of the coating to resist press-fit intramedul-
lary implant insertion.
Materials and Methods
All reported experiments were performed using the Dis-
posable Antibacterial Coating (DAC) (Novagenit Srl,
Mezzolombardo, Italy) hydrogel, a patented, Conformite´
Europe´ene (CE)-marked medical device, intended to be
used as a disposable, fast-bioresorbable antibacterial coat-
ing for implants such as joint prostheses or osteosynthesis.
DAC hydrogel is not cleared for use in the United States by
the FDA.
DAC hydrogel, previously shown to meet the UNI EN
ISO 11137-10993-1, 10993-3, 10993-5, 10993-6, 10993-9,
10993-10, 10993-11, 10993-13, ISO 13781:1997, ASTM F
1635-11 standards for safety (Novagenit Srl, data on file),
is composed of covalently linked hyaluronan and poly-
D,L-lactide; complete hydrolytic degradation of the
hydrogel is supposed to take place in vivo [35]. The
hydrogel was delivered in a fully functional kit, comprising
two separately packaged units: (1) a syringe containing the
DAC1 powder, ready for reconstitution with the active
drug, and (2) a procedure pack containing three compo-
nents for reconstitution and spreading of the resulting
hydrogel (Fig. 1).
The present research was conducted under the multiin-
stitutional collaborative project ‘‘Implant Disposable
Antibacterial Coating (IDAC): A Novel Approach to
Implant-Related Infections in Orthopaedics and Trauma
Surgery,’’ funded by the European Commission, within the
Seventh Framework Programme on Research Technologi-
cal Development and Demonstration under Grant 277988.
Antibiotic Delivery Ability
Studies were performed to evaluate the ability of this
hydrogel to release different antibiotics and antibiofilm
compounds. Double-packaged syringes containing sterile
DAC1 powder were provided by the manufacturer. The
reconstituted hydrogel was studied with regard to its ability
to deliver bactericidal levels of a selection of antibiotic and
antibiofilm compounds (vancomycin, gentamicin, tobra-
mycin, amikacin, N-acetylcysteine [NAC], and sodium
salicylate). All of these compounds were purchased from
Santa-Cruz Biotechnology Inc (Santa Cruz, CA, USA) in
the form of powder, except for gentamicin, which was
obtained in solution at a concentration of 50 mg/mL.
Photometric measurements were performed by means of
a Cobas Integra1 400 Plus analyzer (Roche Diagnostics
Ltd, Rotkreuz, Switzerland) at the Laboratory of Clinical
Pharmacology of the University Hospital of Larissa
(Larissa, Greece). Each release experiment was performed
twice.
Reconstitution of the gel was performed according to the
manufacturer’s instructions. Briefly, syringes prefilled with
60 mg DAC1 powder were reconstituted with 1 mL of
sterile water containing the antibacterial or antibiofilm
substances to obtain a hydrogel with a DAC1 concentra-
tion of 6% (w/v).
The final concentration used for all agents mixed with
1 mL hydrogel was 20 mg/mL, except for tobramycin,
which was used at a concentration of 10 mg/mL. Time
points used in the in vitro release study were 2, 4, 6, 24, 48,
and 96 hours. All release studies were performed in fetal
calf serum (FCS) (Biowest SAS, Nuaille´, France) in
Nunc1 six- and 48-well culture plates (Thermo Scientific,
Milano, Italy). Vancomycin release was also studied in
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human serum (HS) (Life Technologies Corp, Grand Island,
NY, USA) at two starting concentrations of 20 mg/mL and
2 mg/mL.
Hydrogel coating of different biomaterial surfaces
(cobalt-chrome disks, polyethylene disks, titanium disks,
and plastic culture well surfaces) was tested after loading
with vancomycin, gentamicin, amikacin, tobramycin,
NAC, and sodium salicylate, according to the same pro-
cedure. Briefly, a solution of the substance to be tested was
prepared using water for injections, taking into account the
indicated amount to be loaded in the hydrogel and
assuming that the powder reconstitution was carried out
directly with this solution. Then, 1000 lL solution con-
taining the substance to be tested was taken with a syringe
that was connected to a syringe containing DAC powder to
allow the reconstitution according to manufacturer’s
instructions. After complete hydration of the product, the
disk simulating the surface of the orthopaedic implant
under study was placed on an analytical balance to a weight
of 200 mg (10% tolerance) of gel. This quantity of gel was
then spread uniformly over the entire surface of each disk
using the spreader supplied together with the other com-
ponents. The disk with the gel was then immersed in 6 mL
FCS or HS and the container closed to prevent evaporation
and stored at 37 C without shaking. Then, 1 mL release
medium was removed with a precision pipette and sterile
tips at 2, 4, 6, 24, 48, and 96 hours. The 1-mL aspired
aliquot was placed in a 2-mL plastic vial and frozen at
20 C for subsequent analysis. The release medium col-
lected was immediately replaced by 1 mL fresh FCS or HS,
so that the volume was kept at 6 mL until the end of the
study.
Release data for the single experimental time points
were calculated as follows: analytical raw data (expressed
as lg/mL) normalized to the instrumental standard curve
were multiplied with the total buffer volume (mL) used for
incubation to determine substance quantity (lg). The
incubation volume was kept constant throughout the
experiment by integrating at the moment of sampling the
volume with fresh buffer. This procedure unavoidably
leads to dilution. As a consequence, the overall quantity (in
lg) for a given time point was determined by adding the
amount of substance taken away in sampling the previous
time points. Finally, the substance release was expressed as
the percentage of the total quantity initially loaded (ie,
concentration of the substance inside the hydrogel [lg
substance/lg hydrogel] 9 quantity of hydrogel loaded on
the disc [lg]).
In a separate experimental procedure, vancomycin
concentration was also tested on sand-blasted titanium and
chrome-cobalt disks (AdlerOrtho Srl, Milano, Italy) by
means of a microbiologic assay, using a methicillin-resis-
tant Staphylococcus aureus strain (MRBP-2) from the
collection of the IRCCS Galeazzi Institute (Milan, Italy).
The biologic measure of the antibiotic concentration was
performed on the basis of its inhibitory effect (measure-
ment of the inhibition zone diameter). To this aim, the
inhibitory effect of the sample was compared with the
inhibitory effect of graded doses of a standard. By using a
calibration curve of different concentrations of antibiotic
and calculating the regression equation, antibiotic con-
centration in elution fluids can be calculated. The following
algorithm was used to calculate the antibiotic
concentration:
log antibiotic concentration lg=mL½  ¼ intercept
 slope inhibition zone diameter mmð Þ½ 
Antibacterial Activity
The antibacterials tests were aimed at assessing the effects
of the hydrogel coating, either pure or loaded with anti-
bacterials, on bacterial growth and biofilm formation on
common orthopaedic biomaterials.
Minimum Inhibitory Concentration
For the purpose of this study, minimum inhibitory con-
centration (MIC) was defined as the lowest concentration
of antibacterial substance in the presence of which the
tested microorganism was not able to grow. MIC values
were determined by the broth microdilution method.
To evaluate any effect of the gel on the MIC values, the
test was conducted for each strain and substance on the gel
alone, on the antibacterial/antibiofilm substance alone, and
on the gel supplemented with the antibacterial/antibiofilm
substances.
Fig. 1 Spreading of the hydrogel on a titanium prosthesis through a
suitable syringe spreader is shown.
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Gentamicin, vancomycin, and NAC were mixed into the
gel to assess MIC tests and antibiofilm activities. These
compounds were selected because gentamicin and vanco-
mycin are among the most used antibiotics for local
administration and also have different steric and chemical
properties, so they may behave differently when mixed
with the hydrogel. NAC was chosen as this is one of the
few antibiofilm agents that is safe for parenteral use in
humans and also has an antibacterial effect [17, 37],
although it is not cleared for local administration in
orthopaedics. Starting concentration, further diluted to test
MIC, was 256 lg/mL for gentamicin and vancomycin and
100 mg/mL for NAC. Concentrations of the tested anti-
bacterial were the same when it was tested alone or in
combination with the hydrogel.
Clinical strains used in this study were selected from the
Microbiology Laboratory collection (stored at 80 C)
from patients of the Center for Reconstructive Surgery of
Osteoarticular Infections of the IRCCS Galeazzi Institute.
These strains were selected for their properties of resis-
tance to antibacterial agents and for their high ability to
produce biofilm on prosthetic materials in vitro. In partic-
ular, we used one clinical strain of methicillin-resistant S
aureus, one of methicillin-resistant Staphylococcus epide-
rmidis, one of Escherichia coli, one of vancomycin-
resistant Enterococcus faecalis, one of Acinetobacter
baumannii, and one of Pseudomonas aeruginosa.
All bacterial strains were grown overnight in tryptic soy
broth (TSB) (Biomerieux, Marcy l’Etoile, France) at 37 C
under aerobic conditions, unless specified otherwise.
Reconstitution of the gel was performed according to
manufacturer’s instructions as described above.
For each strain, a bacterial suspension with a density
equal to 0.5 McFarland (1 9 108 colony-forming units
[CFU]/mL) was prepared and properly diluted to obtain a
concentration of 1 9 104 CFU/mL; then 10 lL was inoc-
ulated in a 96-well microplate containing 100 lL TSB and
a serial dilution of the tested substance. The last column of
the plate was used as a positive control of growth. After
incubation at 37 C for 24 hours, the MIC values were read,
which corresponded to the last concentration in which there
was visible bacterial growth by formation on the bottom.
Assays were performed in duplicate for each strain, and if
the MIC of two tests differed for more than one well, the
assay was repeated.
Antibiofilm Activity
The same methicillin-resistant S aureus and S epidermidis
strains as indicated above were used to evaluate the anti-
biofilm activity on mature biofilm of the gel reconstituted
with vancomycin, gentamicin, and NAC. The hydrogel
supplemented with vancomycin (20 mg/mL), gentamicin
(20 mg/mL), or NAC (100 mg/mL) was compared to each
antibacterial alone.
Sand-blasted titanium, cobalt-chrome, and polyethylene
disks were used as substrate for biofilm formation. Briefly,
the disks were placed into six-well flat-bottomed sterile
polystyrene microplates (Jet Biofil1; Guangzhou Jet Bio-
Filtration Products Co, Ltd, Guangzhou, China) contain-
ing 5 mL TSB and 200 lL of the bacterial suspension.
The microplates were incubated at 37 C aerobically.
After 24 hours, the exhausted growth medium eventually
containing the nonadherent bacteria was removed and
replaced by 5 mL fresh medium. The plates were incu-
bated for a further 48 hours to obtain the mature biofilm.
Before the treatments, the remaining nonadhering bacte-
ria, if any, were removed by washing three times with
sterile saline solution. For each strain, several disks were
prepared for monitoring the hydrogel activity at different
time points: 2, 4, 6, 24, and 48 hours after the biofilm-gel
contact. Two hundred milligrams (10% tolerance) of gel
was spread over the entire surface of each disk with
mature biofilm and each disk was incubated under proper
conditions with 5 mL fresh TSB. At each time point,
disks were recovered and, after several washes, allowed to
air dry. Subsequently, to evaluate the efficacy of the
hydrogel supplemented with antibacterial or antibiofilm
substances, the whole biomass present on each disk was
determined after different incubation times by the method
described by Christensen et al. [12]. Briefly, air-dried
disks were immersed in a 5% crystal violet solution for 15
minutes and, after several washings, were air dried again.
The estimation of biofilm biomass was performed by
elution of the biofilm bound to crystal violet with 3 mL
ethanol (96%) followed by the determination of the
absorbance of 100 lL of eluted dye solution at 595 nm
using a microplate photometer (Multiskan FCTM; Thermo
Scientific). Measurements were carried out in triplicate.
Percentage of biofilm reduction was calculated according
to the following formula:
absorbance growth control  absorbance samplesð Þ=½
absorbance growth control  100:
Two more S aureus and S epidermidis strains were
tested at the University of Heidelberg to assess biofilm
formation and bacterial growth inhibition on sand-blasted
titanium at time intervals of 48 hours and 5 to 7 days,
comparing the hydrogel alone to the gel supplemented with
vancomycin (Calbiochem1; Merck KGaA, Darmstadt,
Germany), gentamicin (Refobacin1; Merck KGaA),
meropenem (Hospira; Hospira, Munich, Germany),
rifampicin (Eremfat1; Fatol Arzneimittel GmbH,
Schiffweiler, Germany), ciprofloxacin (Ciprobay1; Bayer
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HealthCare AG, Leverkusen, Germany), daptomycin
(Cubin1; Cubist Pharmaceuticals, GmbH, Nuremberg,
Germany), diclofenac sodium (Sigma-Aldrich, Munich,
Germany), and NAC (Sigma-Aldrich) in concentrations
ranging from 0.2 mg to 100 mg/mL.
Surgical Use Feasibility
Experiments were performed to test the resistance of the
hydrogel coating on an implant surface against removal
after press-fit insertion in bone. These ‘‘drag tests’’ were
performed in both an ex vivo animal model and human
femurs.
Rabbit Tibias
Sixty milligrams of DAC powder was mixed with 1 mL
water containing 1% methylene blue (Merck). The gel
was then applied to a sand-blasted titanium rod (Adler-
Ortho) (4.0-mm diameter, 25-mm length, mean 5.6-lm
surface roughness) until the implant was completely
covered. A hole with a diameter of 4.1 mm was drilled in
the tibial medullary canals in the tibial plateaus of six
rabbit previously explanted tibias (New Zealand White
rabbits) (the tibias were kindly provided by the Central
Laboratory Animal Research Facility of the University
Medical Center Utrecht, Utrecht, The Netherlands). Each
rod covered with gel was inserted into one of the tibias.
The tibias were sawed in half with an electrical saw.
Photographs were taken of the implants and of both sides
of the tibias. To calculate the amount of hydrogel that
remained on the implants, the implant alone and the
implant covered with hydrogel before and after implan-
tation were weighed, as well as the amount of gel that
was squeezed out of the canal after inserting the titanium
rod.
Human Femurs
In 10 human femurs, the femoral head was removed with
an oscillating saw and the femoral shaft reamed with
dedicated instruments until the proper size for press-fit
implant of a straight, sand-blasted (mean 6-lm surface
roughness) titanium standard femoral stem (Recta; Adler-
Ortho Srl) was achieved. Before implantation, 1% 300 mg
DAC powder, reconstituted with 5 mL water for injections,
containing 1% methylene blue (Merck) for further identi-
fication and also, in six femurs, vancomycin at a
concentration of 2% w/v were applied on the prosthesis
with a suitable spreader until the implant surface was
completely covered. With 5 mL gel, it was possible to coat
up to two medium-sized prosthetic stems. The spreading
time ranged from 3 to 5 minutes. The implant covered with
gel was then inserted into the femoral canal. The blue
substance that squeezed out after implantation was col-
lected and weighed. After press-fit insertion of the
prosthesis, the femur was sawed in half longitudinally on
the medial and lateral aspects using an oscillating saw,
allowing opening of the shaft for inspection of the inner
surface in contact with the prosthesis. Photographs were
then taken of the implant and the femur on both sides and
surface coverage by the hydrogel stained with methylene
blue was visually analyzed. In the six femurs with vanco-
mycin, the weight of the prosthesis before the coating and
after explantation was compared to assess the amount of
hydrogel on the prosthesis after insertion in the femoral
canal.
Statistical Analysis
Statistical analysis was conducted with a two-way ANOVA
followed by Bonferroni’s correction using statistical soft-
ware from VassarStats (Poughkeepsie, NY, USA).
Significance level was set at p values of less than 0.05.
Results
Antibiotic Delivery Ability
Peak release was observed at 2 hours after submerging the
coated disks into the serum, regardless of the compound,
the surface, or the temperature at which incubation took
place. The release patterns of gentamicin, amikacin,
tobramycin, vancomycin, NAC, and sodium salicylate are
reported on different substrates (Fig. 2). At 48 to 72 hours,
the release of all tested compounds was almost complete or
complete. The concentration at 96 hours was directly
proportional to the initial concentration used to prepare the
hydrogel. Thus, when 20 mg/mL was used as a starting
concentration, the lowest level reached at 96 hours ranged
from 200 to 300 lg/mL, while when an initial concentra-
tion of 2 mg/mL was used, the concentration at 96 hours
was approximately 20 lg/mL.
Microbiologic assay showed, for vancomycin tested at
an initial concentration of 20 mg/mL or 50 mg/mL, peak
concentrations were approximately 1800 lg/mL and
3500 lg/mL, respectively, at 2 hours, with a gradual
decline to 600 to 1000 lg/mL (polyethylene disks) or 350
to 540 lg/mL (cobalt-chrome disks) at 96 hours, respec-
tively. Using the same approach and HS instead of FCS,
peak concentration showed a slight delay (4 hours instead
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of 2 hours), while at 96 hours, final concentrations over-
lapped those measured in FCS.
In summary, both photometric measurement and
microbiologic assays showed that all tested compounds
were completely or nearly completely released from the
hydrogel within 96 hours, with a peak release varying
between 2 and 4 hours, depending on the medium, with
concentrations measured at each time interval directly
proportional to the starting ones.
Antibacterial Activity
Minimum Inhibitory Concentration
The hydrogel alone did not show a measurable antibacterial
activity, while the MICs for gentamicin, vancomycin, and
NAC were unchanged or reduced up to four times when these








Fig. 2A–F Graphs show the release kinetics of (A) gentamicin, (B)
amikacin, (C) tobramycin, (D) vancomycin, (E) NAC, and (F)
sodium salicylate from DAC hydrogel on different substrates (cobalt-
chrome, polyethylene, titanium). Peak concentration was observed
after 2 hours, regardless of the loaded compound and initial
concentration.
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Antibiofilm Activity
At different time points, the hydrogel supplemented with
vancomycin, gentamicin, or NAC reduced the amount of
mature biofilm to a larger extent that that measured for any
antibacterial alone on sand-blasted titanium disks (Fig. 3).
The difference was evident from the very first hours of
incubation and was maintained until the latest observation
point of 48 hours. Similar results were obtained on poly-
ethylene disks and chrome-cobalt substrates at 2 and 48
hours (Table 2).
The hydrogel supplemented with various antibacterials
showed a remarkable inhibition of biofilm formation and of
planktonic bacterial growth of the tested strains, compared
to the hydrogel alone (Table 3). Interestingly, pure anti-
biofilm agents, such as diclofenac sodium, only prevented
biofilm formation but did not show any effect on plank-
tonic bacteria growth. At the concentrations tested, NAC
showed a progressively more effective bacterial growth
inhibition and antibiofilm effect.
Surgical Use Feasibility
Rabbit Tibias
After implantation of the gel-covered titanium rod, the
mean ± SD amount of hydrogel adhering to the rod was
0.08 ± 0.01 g (range, 0.07–0.09 g) (58%) and the mean
amount extruded during implantation was 0.06 ± 0.01 g
(42%). On average, 0.24 mg/mm2 covered the surface of
the rod after implantation.
After cutting the tibia in half, the implant showed
methylene blue staining by the gel on the entire rod sur-
face. The most intense blue staining however could be seen
on both halves of the tibia. Interestingly, the staining on the
inside of the tibia was most intense at the bottom and the
upper part of the implant site. The middle part was either
less intensely stained or not at all.
Human Femurs
After implantation of the coated prosthesis and opening of
the femurs, the implant appeared still completely covered
with blue hydrogel. Furthermore, the inside of the femur
was heterogeneously covered with blue hydrogel over the
complete length of the implant (Fig. 4). Some of the bone
marrow adhered to the corresponding place of the implant,
which caused some absence of blue staining on the inside
of the femur. Observing the residual traces of the dye on
the inner side of the bone shafts, it was noted that most of
the tissue staining appeared in areas of greater contact, ie,
in the apical zones, corresponding to areas just below the
greater trochanter. In deeper distal areas, it was noticed that
different portions of the spongy bone had remained
adherent to the stem of the prosthesis, confirming the
remarkable adhesion of the hydrogel and the complete
absence of visible dragging. On visual inspection, no dif-
ference in staining intensity at the surface of the implant
was noted, comparing different experiments or when the
hydrogel was used alone or mixed with 2% vancomycin.
Due to the mixing of the hydrogel with bone marrow,
the substance that squeezed out during implantation toge-
ther with the amount of gel covering the implant after
implantation weighed more than the amount of gel applied
before implantation. A mean of 78% ± 16% (range,
71%–85%) of the hydrogel initially applied to the pros-
thesis was retrieved on the explanted implants.
Discussion
Implant-related infections represent one of the most severe
complications in orthopaedics, with a reported incidence














Staphylococcus epidermidis 4* 1* 2* 0.5* 12.5 6.125
Staphylococcus aureus 0.5 0.5 2 1 25* 6.125*
Enterococcus faecalis 2* 0.5* [ 128 64 25* 6.125*
Escherichia coli [ 128 [ 128 8 4 25* 6.125*
Acinetobacter baumannii [ 128 [ 128 [ 128 [ 128 12.5 6.125
Pseudomonas aeruginosa [ 128 [ 128 [ 128 [ 128 25* 6.125*
* A reduction of minimum inhibitory concentration of at least four times was observed using hydrogel + antibiotic in comparison to the
antibiotic alone.
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ranging from less than 1% to 3% after joint arthroplasty [9,
13, 30, 36] to 2% to 5% after spine surgery [14, 40] and
even higher after severe trauma fixation [8, 31, 32]. To
overcome this problem, various strategies to provide
implants with an antibacterial coating have been proposed
[19, 23]. A first approach includes porous materials, loaded
with antibiotics; among these, antibiotic-loaded poly-







Fig. 3A–F Graphs show antibiofilm activity on titanium disks of (A,
B) vancomycin alone and hydrogel + vancomycin, (C, D) gentami-
cin alone and hydrogel + gentamicin, and (E, F) NAC alone and
hydrogel + NAC in (A, C, E) S aureus and (B, D, F) S epidermis.
Hydrogel supplemented with the different substances shows a greater
antibiofilm activity when compared with the gel alone or with the
substances alone (**p \ 0.001; *p \ 0.05).
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the best known. However, PMMA is a resin not originally
designed to act as a local drug delivery carrier, is not
suitable to coat osteosynthesis or cementless implants, is
nonbiodegradable, and is prone to microbial adhesion and
biofilm formation. Also, it may only be loaded with a
restricted range of antibiotics and the long-lasting release
may induce antibiotic resistance [27, 33, 38]. Other solu-
tions, such as cancellous bone [10], collagen sponges
[24, 24], or newer biodegradable elution systems [6, 26],
share the goal of keeping the implant surface sterile and are
biodegradable. Interestingly, most of these controlled-
release systems are powerful therapeutic tools, showing
high local antibiotic concentrations over a short term. For
example, in an allograft system, independent of initial
concentrations and time of impregnation, approximately
75% of the adsorbed vancomycin and approximately 99%
of netilmicin elute within only 120 hours [41]. However,
potential drawbacks of these elution systems when used as
implant coatings include their limited antibacterial spec-
trum, possible exposure of the surviving bacteria to
subinhibitory concentrations of antibiotics, unproven effi-
cacy against biofilm-embedded bacteria or at preventing
biofilm formation [15], possible local tissue toxicity and
interference with implant osteointegration, and high costs
[1, 4, 18, 25]. Another technologic approach, aimed at
changing the physical/chemical composition of the implant
surface permanently, such as silver-impregnated surfaces
[20] or antibiotics or antimicrobial peptides covalently
attached to an implant surface [2, 3, 39], raises still more
concerns regarding long-term tissue toxicity, osteointe-
gration, and bacterial-resistance induction, posing
regulatory dilemmas that appear difficult to solve, as the
implant becomes more and more similar to an active drug
inserted into the body [11, 16]. Moreover, given the fact
that the implant coating should be applied during manu-
facture, any new coating (eg, vancomycin instead of
gentamicin) would require new investigations and approval
by local regulatory bodies, with an exponential increase in
time and costs.
In an effort to overcome at least some of the limits of the
current approaches and instead of looking at long-term
release systems, we investigated whether a fast-resorbable
hydrogel was able to be loaded and to deliver antibacterial
compounds locally, thus providing local antibacterial and
antibiofilm protection in vitro and, at the same time, being
capable of resisting declothing when used as a press-fit
implant coating.
Our in vitro data show that all of the tested compounds
were delivered from the hydrogel within 96 hours, with a
peak in the very first hours. The quick time to a complete
release of the antibacterial reduces to a minimum the risk
of induced antibiotic resistance. It also represents a change
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permanent antibacterial coatings [23]; contrary to this
common vision, our in vitro results support the concept that
the race to the surface is won in the very first hours after
implant insertion in the body [15] and that is the time when
an antibacterial coating needs to exert its function, just as
systemic prophylaxis has been shown to be necessary only
in the short term perioperatively.
In line with this premise, a second goal of this study was to
assess the ability of the antibacterial-loaded hydrogel to
reduce or prevent bacterial colonization and biofilm forma-
tion on a coated implant in vitro. This is, to our knowledge,
the first demonstration that a fast-resorbable biodegradable
hydrogel was able to reduce or prevent biofilm formation in
combination with commonly available antibiotics and anti-
biofilm agents. Concerning this latter achievement, a
number of antibiofilm compounds are currently under study,
but only NAC and some antiinflammatory drugs have shown
antibiofilm activity and are cleared for human use, even if
with different indications [37].
Furthermore, we addressed the ability of the hydrogel
coating to resist press-fit insertion. Coatings of orthopae-
dics implants may in fact be detached, a problem both with
controlled release and tethered systems. For all systems,
the fragility is associated with the significant forces that are
often applied to orthopaedic hardware during insertion
[23]. In our experiments, we showed for the first time that a
hydrogel coating may resist press-fit insertion in an animal
model with a cylindrical nail and in a human femur model
using a common press-fit femoral stem.
Our study had several major limitations. First, con-
cerning the release studies, in our experimental condition, a
rate of fluid exchange of approximately 1/6 of the initial
volume at any fixed interval time was simulated; however,
this is not necessarily what is be found in vivo, where these
values are not necessarily the same and can vary greatly
from one patient to another. Our results suggest that the
tested hydrogel does not behave as a classical sustained-
drug release system, as it was rapidly eluted in the serum,
quickly releasing its content, ie, within the first 2 to 4
hours. The release profile was not altered, regardless of the
compound tested, the medium, the surface that the hydro-
gel was applied to, or the incubation temperature. Further
decrease of concentration of loaded agents appears to be
dependent on starting values and on the rate of fluid




Inhibition of biofilm growth
compared to growth on




Measured after Measured after
48 hours 5–7 days 48 hours 5–7 days
Gentamicin 40 100 None 100 None
10 25 None None None
Rifampicin 50 100 100 None 50
10 100 100 None 40
Vancomycin 50 100 100 100 100
10 100 100 100 100
Cibrofloxacin 1 100 100 100 100
Daptomycin 50 100 100 100 100
10 100 100 100 100
Meropenem 50 100 100 100 100
10 100 100 80 100
N-Acetylcysteine 20 100 100 100 100
2 60 50 100 100
1 60 50 100 100
0.2 None None None None
20 100 100 20 None
4 100 100 None None
Diclophenac 20 100 100 20 None
4 100 100 None None
* All experiments were carried out on titanium discs; data are the mean of triplicates.
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exchange. It should be noted though that, in all the
experimental conditions tested, despite the rapid release,
the concentration remained much higher than the MIC
(from 100 to 10 times higher) when 20 mg/mL was used.
In the case of vancomycin, even when 2 mg/mL was tested
as the starting concentration, the lowest levels obtained
after 96 hours of incubation were close to the recom-
mended trough levels for vancomycin (15–20 lg/mL; MIC
for vancomycin, B 2–4 lg/mL). Obviously, the final con-
centration is directly related to the starting concentration,
which thus seems to be critical for clinical applications.
Concerning the antibacterial activity, a lower MIC for
the antibiotic-loaded hydrogel compared to each substance
tested alone (gentamicin, vancomycin, or NAC) was
observed. However, this phenomenon has only been tested
on a limited number of microorganisms and at a single
antibacterial concentration. As previously published
observations are lacking, further studies are needed to
confirm these data and to evaluate its clinical relevance.
Moreover, the possible mechanism underlying this find-
ing, which may theoretically include increased cell
permeability or longer stability and action of the drug
delivered, has not been determined.
Hydrogel loaded with gentamicin, vancomycin, or NAC
exhibited synergistic antibiofilm activity when compared
with the activity of each agent alone against S aureus and S
epidermidis. This finding is rather unique, since, although
antifouling ability of hyaluronic acid has been previously
reported, a possible synergistic effect of a hydrogel carrier
and an antibacterial substance with regard to biofilm for-
mation has not been described [7, 21]. Once again, the
mechanisms underlying this finding have not been inves-
tigated and may be due to chemical and physical reasons.
For example, in the case of NAC, the hydrogel may prevent
oxidation, maintaining its antibiofilm activity for longer
periods of time. However, we showed a synergistic anti-
biofilm effect of the hydrogel only in vitro, on a limited
number of microorganisms and compounds, and at only
Fig. 4A–E An implant (Size 6) was (A) covered with hydrogel and
(B) implanted in a human femur. (C) Afterwards, the femur was cut
into two halves. Note the blue staining heterogeneously distributed on
the inner surface. (D, E) Both sides of the implant are completely
covered with blue gel and some bone marrow (brown).
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one concentration. Further studies are needed to confirm
these data and to evaluate their clinical relevance.
Utility in surgical situations is demonstrated by retention
of hydrogel on coated implants during the implantation
process. However, even if press-fit insertion in the diaph-
yseal canal of a sand-blasted titanium implant was not
associated with declothing, both with or without vanco-
mycin in the hydrogel coating, the ability of the hydrogel to
coat other commonly used implants, such as acetabular
cups, knee, or shoulder prostheses, plates, or nails, was not
investigated and the effect of different surface finishing or
composition is also open to further research.
In conclusion, our study provides evidence for the first
time that a resorbable hydrogel, composed of covalently
linked hyaluronan and poly-D,L-lactide, is able to quickly
deliver local antibacterial compounds, thus inhibiting bio-
film formation on different substrates and planktonic
bacterial growth in vitro. Intraoperative coating of implants
with the tested hydrogel appears safe and feasible, while
resistance of the coating to scraping during press-fit
implant insertion has been demonstrated. An antibacterial-
loaded hydrogel coating may represent a possible option to
protect orthopaedic implants from bacterial colonization,
provided that further studies will confirm its efficacy
in vivo, as recently reported [22], and in clinical trials.
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